team

  • Shou Kit Hang

    Shou Kit Hang is a Research Associate at TCD, supporting the development and optimization of T cell-based diagnostic assays. With a background in immunology and lab-based research, his work focuses on characterizing T cell responses to viral infections such as HBV and SARS-CoV-2, contributing to the refinement of diagnostic workflows.

  • Ms. Rosella De Dominicis

    Ms. Rosella De Dominicis leads legal strategy and corporate governance at TCD. With extensive experience in pharmaceutical and life sciences law, she ensures that the company operates within a strong legal and ethical framework—supporting compliance, intellectual property, and regulatory affairs.

  • Dr. Alessandro Sidoli, PhD

    Dr. Alessandro Sidoli brings a wealth of leadership experience in biotechnology to his role as CEO of T Cell Diagnostics. He oversees strategic growth, partnerships, and commercialization of the company’s technologies. Under his guidance, TCD is expanding access to scalable, rapid T cell assays that support immune monitoring and patient care.

  • Assistant Professor Anthony Tanoto Tan, PhD

    Dr. Anthony Tanoto Tan is an Assistant Professor at Duke-NUS Medical School with expertise in T cell immunology in viral infections. His work centers on HBV and SARS-CoV-2, encompassing the development of TCR-T cell therapies and the evaluation of immune responses in clinical trials and translational research settings.

  • Assistant Professor Nina Le Bert, PhD

    Dr. Nina Le Bert is an Assistant Professor at Duke-NUS Medical School, specializing in human immunology. Her research focuses on antigen-specific T and B cell responses in viral infections. She has played a key role in elucidating immune responses to HBV and SARS-CoV-2, contributing to the design of targeted immune-based treatments.

  • Professor Antonio Bertoletti

    Professor Antonio Bertoletti is a globally recognized expert in viral hepatitis and T cell immunology. As a faculty member at Duke-NUS Medical School, his pioneering research has deepened our understanding of HBV-specific cytotoxic T cell responses and laid the scientific groundwork for novel T cell-based diagnostics and immunotherapies.